CD38 and Miyoshi myopathy: Regarding the natural history of patients with refractory/relapsed MM after CD38 MoAB therapy, the median OS after daratumumab progression was 21.0 months (95% C.I. 10.7–31.2) for the global cohort and median time to progression on treatment with anti-CD38 MoAB was 7 months (IQR 3-20).